Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85 - A synthetic agent binding at the colchicine site designed to overcome multidrug resistance

British Journal of Cancer

Volumn 75, Issue 4, 1997, Pages 608-613

  Judson, I ^a,c   Briasoulis, E ^b   Raynaud, F ^a,c   Hanwell, J ^a,c   Berry, C ^a,c   Lacey, H ^a,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Multidrug resistance; Neurotoxicity; Tubulin

Indexed keywords

1069C85; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031045148     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.107     Document Type: Article

References (15)

1. Chan HSL, Thorner PS, Haddad G and Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704
2. Cowie F, Pinkerton CR, Philips M, Dick G, Judson I, McCarthy PT and Flanagan, RJ (1995) Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancer. Br J Cancer 71: 877-881
3. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP and Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415-424
4. Durie BGM and Dalton WS (1988) Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 68: 203-206
5. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B and Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666
6. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G and Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190
7. Hodgson ST, (1994) Discovery of 1069C - a novel synthetic antitumour agent with low cross-resistance potential. In Medicinal Chemistry: Principles and Practice, King FD (ed.), p. 241. The Royal Society of Chemistry: Cambridge
8. Hodgson ST, Jenkins DC, Knick V, Rapson EB and Watts SDM (1992) Synthetic and biological properties of 1069C: a new synthetic antitumour agent with very low cross resistance potential. Bioorg Med Chem Lett 34: 1257-1264
9. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon, SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24
10. Raynaud F, Walton M and Judson I (1993) An HPLC assay for the measurement of 1069C85 in biological tissue and fluids. J Chromatogr Biomed Appl 622: 243-248
11. Raynaud FI, Kelland LR, Walton MI and Judson IR (1994) Preclinical pharmacology of 1069C85, a novel tubulin inhibitor. Cancer Chemother Pharmacol 35: 169-173
12. Rowinsky EK, Noe DA, Grochow LB, Bowling MK, Sartorious SE, O'Reilly S, Chen T and Donehower RC (1995) Phase I and pharmacological study of CI-980, a synthetic and structurally unique antimicrotubule agent, on a 72-hour continuous infusion schedule in adults with solid tumors. Proc Am Soc Clin Oncol 14: 459
13. Sklarin NT, Benson L, Roca J, Einzig AI, Wiernik PH, Whitfield LR, Lathia C, Kowal C and Grove W (1995) Phase I study of CI-980: 24-hr infusion schedule. Proc Am Soc Clin Oncol 14: 479
14. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B and Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259
15. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P and van Tellingen O (1996) Altered pharmacokinetics of vinblastine in mdrla P-glycoprotein-deficient mice. J Natl Cancer Inst 88: 994-999